Drugs that are said to slow the progression of Alzheimer’s disease “make no meaningful difference to patients” while increasing the risk of swelling and bleeding in the brain, according to a new ...
PROVIDENCE, R.I., April 1, 2026 /PRNewswire/ -- Bleeding events were far more common than clotting events among patients with cancer in the last phase of life, yet most patients taking blood-thinning ...
Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results